Botulinum Toxin Drug Landscape

As of 2026-11-14, products from AbbVie, Ipsen, Merz, Korea’s Hugel and Daewoong had US glabellar-line approvals; Taiwan’s OBI-858 remained in Phase 3.

OBIGEN reported on 2026-09-07 that over half of participants received only 1 or 2 treatments during its one-year repeat-dose Phase 2; this does not replace Phase 3 primary endpoints.

OBIGEN still targeted Phase 3 completion in 2026 in its 2026-09-07 announcement, followed by a registration application; pivotal endpoint results will determine its progress toward approved products.

Botulinum Toxin Drug Landscape

Type A botulinum toxins for glabellar lines. Potency units are product-specific and are not interchangeable; duration is not ranked across separate trials.

Competitive landscape

AssetCompanyMechanism / routeStageIndicationTrial identifierDealLatest developmentSource
Botox Cosmetic / onabotulinumtoxinAAbbVieUSBotulinum neurotoxin type AIntramuscularUS approvedGlabellar lines and label-specific indications——Established approved product; units are not interchangeabledailymed.nlm.nih.gov
Dysport / abobotulinumtoxinAIpsenFranceBotulinum neurotoxin type AIntramuscularUS approvedGlabellar lines and label-specific indications——Ipsen product; aesthetic commercialization rights are distinctdailymed.nlm.nih.gov
Xeomin / incobotulinumtoxinAMerzGermanyBotulinum neurotoxin type AIntramuscularUS approvedUpper facial lines, per label——Glabellar-line evidence on label; molecular size does not prove durationdailymed.nlm.nih.gov
Letybo / letibotulinumtoxinAHugelSouth KoreaBotulinum neurotoxin type AIntramuscularUS approvedAdult moderate-to-severe glabellar lines——FDA approval 2024-02-29; 1,271 participants across three trialsfda.gov
Jeuveau / prabotulinumtoxinADaewoong (manufacturer) / Evolus (US commercialization)South Korea / USBotulinum neurotoxin type AIntramuscularUS approvedAdult moderate-to-severe glabellar lines——FDA review identifies Daewoong as manufactureraccessdata.fda.gov
OBI-858OBIGEN PharmaTaiwan760 kDa type A toxin complexIntramuscularTaiwan Phase 3Moderate-to-severe glabellar linesOBI-858-004
OBI-858-005
—Two Phase 3 trials: about 600 participants, 16 centers; primary endpoint: GLS improvement ≥2 grades at Week 4; repeat-dose Phase 2 completedobigenpharma.comobigenpharma.com
JSONCSV

Taiwan and Asia

Taiwan’s OBIGEN announced enrollment of approximately 600 participants across 16 centers in its two pivotal trials on 2026-03-16; a US Phase 2 IND is distinct from marketing approval. Korea’s Hugel Letybo and Daewoong-manufactured, Evolus-marketed Jeuveau have US approvals.